BioNTech settles Covid-19 patent dispute with CureVac
UK’s GSK will receive $370mn and 1% of sales of some vaccines as part of the deal
Related reading
BioNTech to cut fifth of workforce as it winds down Covid vaccine production
German biotech is shifting towards cancer treatments
Co-founders behind pioneering Covid vaccine to step down from BioNTech
Uğur Şahin and Özlem Türeci are leaving German group to launch their own mRNA venture
Merck nears deal for flu-prevention biotech Cidara
San Diego company’s lead drug is a potential alternative to vaccines for vulnerable patients
UK biotech keeps selling itself to America
A shortage of late-stage capital pushes the biggest prizes into US hands
Big pharma’s scramble over the patent cliff will be costly
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
Merck transforms itself through dealmaking as clock ticks on top-selling drug
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda